000813.SHE Dezhan HealthCare Co Ltd
- Market cap
- CNY 6.35B
- P/E
- -
- P/B
- 1.30x
- ROE
- -3.0%
- Dividend yield
- 0.02%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000813.SHE undervalued?
Graham numberThe Graham number of Dezhan HealthCare Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dezhan HealthCare Co Ltd fundamental analysis
No fundamental analysis for Dezhan HealthCare Co Ltd yet.
Dezhan HealthCare Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dezhan HealthCare Co Ltd
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, …
Full company profileDezhan HealthCare Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dezhan HealthCare Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.44B | 2.22B | 3.29B | 1.77B | 963M | 734M | 571M | 498M | 466M | 397M | 307M |
| Gross Profit | 1.22B | 2.00B | 3.05B | 1.40B | 668M | 473M | 211M | 275M | 296M | 223M | 137M |
| Operating Income | 775M | 939M | 1.05B | 380M | 352M | -37.2M | -119M | 80.2M | -42.5M | -174M | -182M |
| EBITDA | 794M | 948M | 1.08B | 357M | 303M | 128M | -64.3M | 25.7M | -1.32M | -327M | -153M |
| Net Income | 662M | 797M | 931M | 337M | 285M | -57.6M | -47.0M | 83.3M | -20.4M | -345M | -138M |
| EPS | 0.30 | 0.36 | 0.42 | 0.15 | 0.13 | -0.03 | -0.02 | 0.04 | -0.01 | -0.16 | -0.07 |
| Balance Sheet | |||||||||||
| Total Assets | 3.93B | 5.14B | 5.92B | 5.93B | 6.40B | 5.78B | 5.67B | 5.38B | 5.32B | 4.87B | 4.74B |
| Total Liabilities | 175M | 594M | 640M | 316M | 446M | 308M | 390M | 137M | 155M | 299M | 299M |
| Shareholders' Equity | 3.75B | 4.55B | 5.28B | 5.61B | 5.90B | 5.37B | 5.29B | 5.24B | 5.16B | 4.64B | 4.53B |
| Cash & Short-term Investments | 1.69B | 1.92B | 1.44B | 3.57B | 3.51B | 1.89B | 2.60B | 2.80B | 2.53B | 1.81B | 691M |
| Total Debt | 384K | 384K | 6.29M | 5.00M | 56.9M | 12.4M | 9.07M | 5.50M | 14.7M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 262M | 385M | 380M | 1.56B | 828M | 42.4M | 162M | 128M | -14.6M | 4.72M | - |
| Capital Expenditure | 75.0M | 112M | 68.6M | 65.1M | 110M | 127M | 67.6M | 160M | 167M | 236M | 190M |
| Free Cash Flow | 187M | 273M | 311M | 1.49B | 717M | -84.5M | 94.2M | -31.9M | -181M | -231M | -225M |
| Ratios | |||||||||||
| ROE | 17.6% | 17.5% | 17.6% | 6.0% | 4.8% | -1.1% | -0.9% | 1.6% | -0.4% | -7.5% | -3.0% |
| ROA | 16.8% | 15.5% | 15.7% | 5.7% | 4.4% | -1.0% | -0.8% | 1.5% | -0.4% | -7.1% | -2.9% |
| Net Profit Margin | 45.9% | 35.9% | 28.3% | 19.0% | 29.6% | -7.8% | -8.2% | 16.7% | -4.4% | -87.0% | -45.0% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dezhan HealthCare Co Ltd dividends
- Dividend yield
- 0.02%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 1, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.48M | 0.00 | - |
| 2024 | CNY 79.7K | 0.00 | - |
| 2023 | CNY 29.1K | 0.00 | 0.0% |
| 2022 | - | - | - |
| 2021 | CNY 470M | 0.21 | - |
| 2020 | CNY 30.9K | 0.00 | 0.0% |
| 2019 | CNY 30.9K | 0.00 | 0.0% |
| 2018 | CNY 30.9K | 0.00 | 0.0% |
| 2017 | CNY 30.9K | 0.00 | 0.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 15:10 on May 24, 2017.
Who owns Dezhan HealthCare Co Ltd
- Insiders 49.00%
- Institutions 0.72%
- Public & others 50.28%
- Shares outstanding 2.10B
- Free float 1.35B
Dezhan HealthCare Co Ltd company profile
- Company name
- Dezhan HealthCare Co Ltd
- Ticker
- 000813.SHE
- ISIN
- CNE000000VV8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Apr 9, 1998
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,067
- Fiscal year end
- December
- Address
- First Shanghai Center, Beijing, China, 100025
- Phone
- 86 10 6585 8557
- Website
- dezhanhealthcare.com
About Dezhan HealthCare Co Ltd
Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People's Republic of China. The company offers atorvastatin calcium tablets, amlodipine-atorvastatin calcium tablets, warfarin sodium tablets, trimetazidine hydrochloride tablets, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, hydroxyurea tablets, colchicine tablet, and oseltamivir phosphate capsules. It also involved in the provision of biopeptides, industrial hemp, and medical service business. Dezhan Healthcare Company Limited was founded in 1980 and is based in Beijing, the People's Republic of China.
Dezhan HealthCare Co Ltd management
6- Mr. Wei LiuCo-Chairman & GM · born 1970
- Ms. Ling WuChief Financial Officer · born 1982
- Mr. Ye LiuChief Scientist · born 1957
- Mr. Tao GaoDeputy GM, Director & Secretary of the Board · born 1979
- Ms. Jinghong ZhangDeputy General Manager · born 1974
- Mr. Lang ChenAccounting Supervisor